Primary biliary cholangitis, or PBC, is an autoimmune liver disease that can cause liver failure and death. In this test-specific episode of the "Answers From the Lab" podcast, Anne Tebo, Ph.D., Co-Laboratory Director of the Antibody Immunology Laboratory and Professor at DLMP, Mayo Clinic, explains how Mayo Clinic Laboratories' new testing expands the options for diagnosing PBC.

The presence of anti-mitochondrial antibodies or AMA is hallmark feature of PBC. However, a subset of PBC patients are seronegative for AMA and testing for the PBC-specific autoantibodies, anti-Sp100 and anti-gp210 antibodies may be useful in their evaluation. Mayo Clinic Laboratories has launched new ELISA serum tests that identify antibodies to Sp100 and GP210 — two other antibodies associated with PBC — in AMA-negative patients. The tests can be ordered individually (Test IDs: SP100 and GP210) or together in a new PBC panel (Test ID: PBC2).

"Testing for SP100 and GP210 antibodies, in addition to AMA, is recommended for all patients with suspicion for PBC. This is really an appropriate standard of care," Dr. Tebo says.

Mayo Clinic Laboratories' new PBC Antibody Panel (Test ID: PBCPN) evaluates at-risk or previously diagnosed PBC patients with new features of other liver or autoimmune diseases. It covers AMA, Sp100, GP210, and two indirect fluorescent antibodies.

"The comprehensive panel provides an optimal approach, as it has the potential to support the diagnosis of AMA-positive and -negative PBC patients, as well as identify patients with coexisting systemic autoimmune diseases," Dr. Tebo says.

Listen to learn more about Mayo Clinic Laboratories' SP100, PBCPN, PBC2, and GP210 testing.

Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

PBCPN  | Primary Biliary Cholangitis Antibody Panel, Serum

PBC2   | SP100 and GP210 Antibodies, IgG, Serum

SP100   | SP100 Antibody, IgG, Serum

GP210   | GP210 Antibody, IgG, Serum

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less